Theralase® Research - One of the Top 10 Most Downloaded Papers
June 24, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Phase Ib NMIBC Clinical Study Published
June 21, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 21, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q122 Interim Financial Statements
May 30, 2022 17:53 ET
|
Theralase Technologies Inc.
TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
April 05, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
December 20, 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
Theralase Expands Intellectual Property Portfolio
December 09, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Theralase Releases 3Q21 Financial Statements and Newsletter
November 29, 2021 18:00 ET
|
Theralase Technologies Inc.
TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
SESN NOTICE: Rosen, Trusted Investor Counsel, Encourages Sesen Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action – SESN
October 13, 2021 18:15 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
August 30, 2021 18:15 ET
|
Theralase Technologies Inc.
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research...
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...